Scarica l'app Stockscreener
0.3501
3.77%
-0.0138
Precedente Chiudi:
$0.3638
Aprire:
$0.36
Volume 24 ore:
304.09K
Relative Volume:
0.27
Capitalizzazione di mercato:
$65.23M
Reddito:
-
Utile/perdita netta:
$-41.23M
Rapporto P/E:
-0.5001
EPS:
-0.7
Flusso di cassa netto:
$-11.54M
1 W Prestazione:
+0.55%
1M Prestazione:
-39.51%
6M Prestazione:
-31.55%
1 anno Prestazione:
-77.56%
Intervallo 1D:
$0.3413
$0.3663
Intervallo di 1 settimana:
$0.3413
$0.4034
Portata 52W:
$0.3214
$2.34
Renovaro Inc Stock (RENB) Company Profile
Nome
Renovaro Inc
Settore
Industria
Telefono
45 39179840
Indirizzo
CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES
Confronta RENB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RENB
Renovaro Inc
|
0.3501 | 65.23M | 0 | -41.23M | -11.54M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.12 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
566.95 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
630.47 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.45 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
248.70 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Renovaro Inc Borsa (RENB) Ultime notizie
Market Watch: Renovaro Inc (RENB)’s Noteworthy Gain, Closing at 0.37 - DWinneX
Investor’s Delight: Renovaro Inc (RENB) Closes Weak at 0.39, Down -16.49 - DWinneX
AI medicine company Renovaro to use Nebul's AI cloud infrastructure - Data Center Dynamics
Renovaro Inc [RENB] stock for 1,448 USD was sold by William Anderson Wittekind - knoxdaily.com
RENB’s 52-Week Rollercoaster: From $0.32 to $2.34 – What’s Next for Investors? - investchronicle.com
Renovaro BioSciences expands collaboration with Nebul - MSN
Insider’s View: Deciphering Renovaro Inc (RENB)’s Financial Health Through Ratios - DWinneX
Renovaro Inc (RENB)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com
Renovaro Expands Partnership With Nebul To Accelerate AI-Driven Cancer Diagnostics - Nasdaq
Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs | RENB Stock News - GuruFocus
Renovaro (ticker) and Nebul Enhance Partnership to Boost Diagnostic Innovations | RENB Stock News - GuruFocus
Renovaro Inc. Expands Collaboration with Nebul to Enhance Early Cancer Detection Through Advanced AI Technology - Nasdaq
Renovaro Secures High-Powered Computing from Nebul Through - GlobeNewswire
Renovaro's New AI Partnership Targets Breakthrough in Early-Stage Lung Cancer Detection Technology - Stock Titan
Renovaro Inc (NASDAQ: RENB) Has Great Upside Potential - Stocksregister
Renovaro faces Nasdaq delisting over share price issue By Investing.com - Investing.com Canada
Renovaro faces Nasdaq delisting over share price issue - Investing.com
Renovaro Inc. (NASDAQ:RENB) Shares Purchased by Corebridge Financial Inc. - Defense World
Renovaro closes merger transaction with BioSymetrics - Pharmaceutical Business review -
Renovaro merges with BioSymetrics to boost AI drug discovery - Investing.com
Renovaro merges with BioSymetrics to boost AI drug discovery By Investing.com - Investing.com South Africa
Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven B - GuruFocus
Walmart stands by its annual financial outlook but pulls back its 1Q view amid tariff uncertainty - The Globe and Mail
Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine - GlobeNewswire
Major AI Breakthrough: Renovaro-BioSymetrics Merger Creates Powerhouse in Precision Medicine - Stock Titan
Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and ... - Bluefield Daily Telegraph
Morgan Stanley (MS) Is About to Report Q1 Earnings This Week. Here’s What to Expect - The Globe and Mail
CPKC to report first-quarter 2025 earnings results on April 30 - The Globe and Mail
3 Reasons FDP is Risky and 1 Stock to Buy Instead - The Globe and Mail
2 Reasons to Like AMZN and 1 to Stay Skeptical - The Globe and Mail
Predictive Oncology Ends Merger Talks with Renovaro - TipRanks
RENB: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
Renovaro says Predictive Oncology terminates merger transaction - MSN
RENB stock touches 52-week low at $0.4 amid sharp annual decline - Investing.com Canada
Renovaro Biosciences faces merger setback with Predictive Oncology - Investing.com India
Sector Update: Health Care - marketscreener.com
Health Care Stocks Tumble On Multiple Fronts - Finimize
Renovaro Says Predictive Oncology Terminates Merger Transaction With Co - marketscreener.com
RENB stock touches 52-week low at $0.4 amid sharp annual decline By Investing.com - Investing.com South Africa
Renovaro Biosciences faces merger setback with Predictive Oncology By Investing.com - Investing.com South Africa
Renovaro BioSciences (RENB) Challenges Merger Termination - GuruFocus
Renovaro Biosciences Announces Breach Of Agreement By Predictive Oncology, Legal Action Pending - Nasdaq
Renovaro Says Predictive Oncology Terminates Merger Deal; Shares Fall - MarketScreener
Renovaro Provides Update to Definitive Agreement with Predictive Oncology - GlobeNewswire
3 Quantum Computing Stocks to Buy Now, According to Analysts – 4/2/2025 - The Globe and Mail
Charles Schwab Investment Management Inc. Buys 163,160 Shares of Renovaro Inc. (NASDAQ:RENB) - Defense World
Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Predictive Oncology pushing forward with Renovaro merger despite $10.8M loss in 2024 - The Business Journals
Predictive Oncology Advances AI Merger Plans Despite $10.8M Loss: Key Strategic Moves Revealed - Stock Titan
Renovaro Inc Azioni (RENB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Renovaro Inc Azioni (RENB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| William Anderson Wittekind | 10% Owner |
Jul 17 '24 |
Sale |
1.46 |
16,362 |
23,889 |
841,433 |
| William Anderson Wittekind | 10% Owner |
Jul 15 '24 |
Sale |
1.41 |
21,954 |
30,955 |
875,795 |
| William Anderson Wittekind | 10% Owner |
Jul 10 '24 |
Sale |
1.51 |
75,000 |
113,250 |
894,645 |
| William Anderson Wittekind | 10% Owner |
Jul 11 '24 |
Sale |
1.51 |
14,896 |
22,493 |
897,749 |
| William Anderson Wittekind | 10% Owner |
Jul 09 '24 |
Sale |
1.53 |
4,630 |
7,084 |
969,645 |
| William Anderson Wittekind | 10% Owner |
Jul 05 '24 |
Sale |
1.55 |
60,000 |
93,000 |
974,275 |
| William Anderson Wittekind | 10% Owner |
Jul 03 '24 |
Sale |
1.51 |
50,000 |
75,500 |
1,034,275 |
| William Anderson Wittekind | 10% Owner |
Jul 01 '24 |
Sale |
1.56 |
60,000 |
93,600 |
1,118,828 |
| William Anderson Wittekind | 10% Owner |
Jul 02 '24 |
Sale |
1.54 |
34,553 |
53,212 |
1,084,275 |
| William Anderson Wittekind | 10% Owner |
Jun 26 '24 |
Sale |
1.57 |
50,000 |
78,500 |
1,193,499 |
1.36%
0.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):